2/26
07:30 am
alt
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Low
Report
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
2/17
09:02 pm
alt
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances [Yahoo! Finance]
2/3
03:55 pm
alt
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
Neutral
Report
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
2/2
10:02 am
alt
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
1/29
05:54 pm
alt
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Medium
Report
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
1/29
01:31 pm
alt
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Low
Report
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
1/29
07:41 am
alt
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
09:25 pm
alt
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
High
Report
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
1/27
06:00 pm
alt
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
High
Report
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/5
07:54 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
Low
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
1/5
07:30 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Medium
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
12/19
07:02 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
12/19
06:30 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
12/1
07:44 am
alt
Altimmune announces CEO transition [Seeking Alpha]
Medium
Report
Altimmune announces CEO transition [Seeking Alpha]
12/1
07:30 am
alt
Altimmune Announces CEO Transition and Succession Plan
Medium
Report
Altimmune Announces CEO Transition and Succession Plan